Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21651973 | 0.90 | RET (0.49) | RETCYP46A1SHMT2CYP1A2CYP2D6 | |
| SCHEMBL25502453 | 0.89 | RET (0.51) | RETCYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL20069627 | 0.87 | RET (0.52) | RETCYP46A1CYP1A2CYP2D6MAPT | |
| SCHEMBL20147868 | 0.86 | RET (0.47) | RETCYP46A1SHMT2CYP1A2CYP2D6 | |
| SCHEMBL20069459 | 0.85 | RET (0.51) | RETCYP46A1SHMT2TP53 | |
| SCHEMBL20158569 | 0.81 | RET (0.51) | RETCYP46A1CYP1A2CYP2D6MAPT | |
| SCHEMBL25502455 | 0.81 | RET (0.51) | RETCYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL20206049 | 0.80 | RET (0.49) | RETCYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL22857003 | 0.80 | RET (0.49) | RETCYP46A1SHMT2CYP1A2CYP2D6 | |
| SCHEMBL20158574 | 0.80 | RET (0.49) | RETCYP46A1CYP1A2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885CYP46A1 4055/4885SHMT2 4295/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885CYP46A1 4055/4885SHMT2 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.